Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

Overview of attention for article published in Breast Cancer Research and Treatment, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 2 news outlets
twitter: 1 X user

patent: 3 patents
wikipedia: 3 Wikipedia pages

Readers on

mendeley: 45 Mendeley

Summary News X Patents Wikipedia

So far, Altmetric has seen 1 X post from an account with 286 followers.

Also - Spironolactone is not even fully confirmed to be a good testosterone blocker. This meta analysis subject is not trans feminine patients but instead looks at those who take the drug for other reasons, and includes the affect on sex hormones. https:

09 Jun 2022

Reply Repost Favourite